This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential Essential cookies enable basic functions and are necessary for the website to function properly.

Analytics Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.

Marketing Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Welcome to the ITM Newsroom

Press Releases

ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium

ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium

Read more

ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026

ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026

Read more

ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS 2026 Conference

ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS 2026 Conference

Read more

ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026

February 25, 2026

ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026

Read more

ITM to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 11, 2025

ITM to Present at the 44th Annual J.P. Morgan Healthcare Conference

Read more

ITM Receives U.S. FDA Fast Track Designation for ITM-94 as a Diagnostic Agent for Clear Cell Renal Cell Carcinoma

November 17, 2025

ITM Receives U.S. FDA Fast Track Designation for ITM-94 as a Diagnostic Agent for Clear Cell Renal Cell Carcinoma

Read more

ITM Announces FDA Acceptance of New Drug Application (NDA) and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

November 13, 2025

ITM Announces FDA Acceptance of New Drug Application (NDA) and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Read more

ITM to Participate in Upcoming Investor Conferences

November 10, 2025

ITM to Participate in Upcoming Investor Conferences

Read more

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

October 25, 2025

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Read more

All Press Releases

Upcoming Events

29 May - 02 Jun 2026

ASCO 2026

29 May - 02 June
Chicago, IL, USA. Visit the ASCO Website.

SNMMI 2026

30 May - 02 Jun 2026

SNMMI 2026

30 May to 02 June. Visit the SNMMI Website.

ASTRO 2026

28 Sep - 01 Oct 2026

ASTRO 2026

ASTRO Annual Meeting - American Society for Radiation Oncology (ASTRO)
Sept 28 - Oct 1, Boston, Massachusetts. Visit the ASTRO Website.

EANM 2026

17 Oct - 21 Oct 2026

EANM 2026

17-21 October, Vienna, Austria

ESMO 2026

23 Oct - 27 Oct 2026

ESMO 2026

23-27 October, Madrid, Spain

SNMMI 2026

04 Nov - 07 Nov 2026

SNMMI 2026

Theranostics Conference
Nov 4-7, Bethesda, Maryland. Visit the SNMMI Website.

NANETS 2026

05 Nov - 07 Nov 2026

NANETS 2026

Multidisciplinary NET Medical Symposium
November 5-7, Las Vegas, Nevada. Visit the NANETS Website.

ITM Newsletter — Stay informed about our latest updates!

Kathleen Noonan

Julia Westermeir

ITM Media Contact

Corporate Communications

Kathleen Noonan/Julia Westermeir

Phone: +49 89 329 8986 1500

E-Mail: communications@itm-radiopharma.com